Published in PLoS One on July 19, 2013
PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study | NCT00115765
Testing chemotherapeutic agents in the feather follicle identifies a selective blockade of cell proliferation and a key role for sonic hedgehog signaling in chemotherapy-induced tissue damage. J Invest Dermatol (2014) 0.79
Arctiin blocks hydrogen peroxide-induced senescence and cell death though microRNA expression changes in human dermal papilla cells. Biol Res (2014) 0.75
Cutaneous transcriptome analysis in NIH hairless mice. PLoS One (2017) 0.75
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA (2000) 55.37
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med (2009) 22.23
Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med (2008) 11.86
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet (2009) 8.73
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol (2004) 8.15
The magical touch: genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin. Proc Natl Acad Sci U S A (1999) 7.67
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2005) 7.55
A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science (1999) 6.97
Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science (1995) 6.58
A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages. J Invest Dermatol (2001) 6.12
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol (2008) 5.56
Controls of hair follicle cycling. Physiol Rev (2001) 5.49
Strain-dependent epithelial defects in mice lacking the EGF receptor. Science (1995) 5.22
Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer (2006) 3.15
Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J (1997) 1.96
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol (2010) 1.83
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther (2006) 1.70
Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. Am J Pathol (1997) 1.62
The EGFR is required for proper innervation to the skin. J Invest Dermatol (2008) 1.55
Chemotherapy-induced alopecia: new developments. South Med J (1993) 1.50
Beyond wavy hairs: the epidermal growth factor receptor and its ligands in skin biology and pathology. Am J Pathol (2008) 1.47
Generation and validation of mice carrying a conditional allele of the epidermal growth factor receptor. Genesis (2009) 1.36
Alkaline phosphatase activity and localization during the murine hair cycle. Br J Dermatol (1994) 1.34
Phosphorylation of the tumor suppressor protein p53 by mitogen-activated protein kinases. J Biol Chem (1994) 1.33
Chemotherapy-induced alopecia in mice. Induction by cyclophosphamide, inhibition by cyclosporine A, and modulation by dexamethasone. Am J Pathol (1994) 1.30
p53 is essential for chemotherapy-induced hair loss. Cancer Res (2000) 1.29
Molecular mechanisms of chemotherapy-induced hair loss. J Investig Dermatol Symp Proc (2003) 1.23
Discordance between physicians' estimations and breast cancer patients' self-assessment of side-effects of chemotherapy: an issue for quality of care. Br J Cancer (1997) 1.19
Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet (2005) 1.14
Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis (2003) 1.13
UV-induced squamous cell carcinoma--a role for antiapoptotic signalling pathways. Br J Dermatol (2009) 1.08
Palmitoylation regulates epidermal homeostasis and hair follicle differentiation. PLoS Genet (2009) 1.04
Apoptosis and autophagy: Regulation of apoptosis by DNA damage signalling - roles of p53, p73 and HIPK2. FEBS J (2009) 1.04
A guide to assessing damage response pathways of the hair follicle: lessons from cyclophosphamide-induced alopecia in mice. J Invest Dermatol (2005) 1.03
Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol (2006) 0.98
Cyclophosphamide in treatment of disseminated malignant disease. Br Med J (1961) 0.98
G Protein betagamma subunits augment UVB-induced apoptosis by stimulating the release of soluble heparin-binding epidermal growth factor from human keratinocytes. J Biol Chem (2007) 0.93
A new role for neurotrophins: involvement of brain-derived neurotrophic factor and neurotrophin-4 in hair cycle control. FASEB J (1999) 0.93
Dissecting the impact of chemotherapy on the human hair follicle: a pragmatic in vitro assay for studying the pathogenesis and potential management of hair follicle dystrophy. Am J Pathol (2007) 0.92
Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one? Clin Cancer Res (2007) 0.90
Mechanism of p53-dependent apoptosis induced by 3-methylcholanthrene: involvement of p53 phosphorylation and p38 MAPK. J Biol Chem (2001) 0.88
Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. J Am Acad Dermatol (2006) 0.87
Fas signaling is involved in the control of hair follicle response to chemotherapy. Cancer Res (2004) 0.85
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. Breast Cancer Res Treat (2007) 0.77
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell (2007) 3.58
Familial myeloma. N Engl J Med (2008) 1.96
Comparison of extended colectomy and limited resection in patients with Lynch syndrome. Dis Colon Rectum (2010) 1.88
Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet (2003) 1.80
Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR). Hum Mutat (2008) 1.76
Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol (2004) 1.63
The EGFR is required for proper innervation to the skin. J Invest Dermatol (2008) 1.55
Association between rectal optical signatures and colonic neoplasia: potential applications for screening. Cancer Res (2009) 1.53
Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol (2005) 1.50
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol (2005) 1.50
EGFR enhances early healing after cutaneous incisional wounding. J Invest Dermatol (2004) 1.35
Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol (2005) 1.32
The molecular basis of neurosensory cell formation in ear development: a blueprint for hair cell and sensory neuron regeneration? Bioessays (2006) 1.24
Chemoprevention of UV light-induced skin tumorigenesis by inhibition of the epidermal growth factor receptor. Cancer Res (2005) 1.24
Ultraviolet irradiation induces keratinocyte proliferation and epidermal hyperplasia through the activation of the epidermal growth factor receptor. Carcinogenesis (2005) 1.23
A disorganized innervation of the inner ear persists in the absence of ErbB2. Brain Res (2006) 1.21
TGFBR1*6A may contribute to hereditary colorectal cancer. J Clin Oncol (2005) 1.16
Accuracy of MSI testing in predicting germline mutations of MSH2 and MLH1: a case study in Bayesian meta-analysis of diagnostic tests without a gold standard. Biostatistics (2005) 1.05
SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis Markers (2004) 1.03
Screening adherence in BRCA1/2 families is associated with primary physicians' behavior. Am J Med Genet A (2004) 0.99
Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer. Fam Cancer (2009) 0.98
Analysis of CHEK2 gene for ovarian cancer susceptibility. Gynecol Oncol (2004) 0.97
Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest (2008) 0.96
The effect of calcium and vitamin D supplementation on obesity in postmenopausal women: secondary analysis for a large-scale, placebo controlled, double-blind, 4-year longitudinal clinical trial. Nutr Metab (Lond) (2010) 0.96
Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch syndrome adenomas. Int J Cancer (2007) 0.93
Hereditary chronic lymphocytic leukemia: an extended family study and literature review. Am J Med Genet (2002) 0.92
Innervation of the maxillary vibrissae in mice as revealed by anterograde and retrograde tract tracing. Cell Tissue Res (2003) 0.91
Risk of colon cancer in hereditary non-polyposis colorectal cancer patients as predicted by fuzzy modeling: Influence of smoking. World J Gastroenterol (2006) 0.91
Erbb2 regulates inflammation and proliferation in the skin after ultraviolet irradiation. Am J Pathol (2006) 0.90
Erbb2 suppresses DNA damage-induced checkpoint activation and UV-induced mouse skin tumorigenesis. Am J Pathol (2009) 0.89
History and molecular genetics of Lynch syndrome in family G: a century later. JAMA (2005) 0.88
Phosphate and carbonate salts of calcium support robust bone building in osteoporosis. Am J Clin Nutr (2010) 0.87
Is analysis of lower esophageal sphincter vector volumes of value in diagnosing gastroesophageal reflux disease? World J Gastroenterol (2003) 0.87
EGFR activation and ultraviolet light-induced skin carcinogenesis. J Biomed Biotechnol (2007) 0.84
Familial B-cell chronic lymphocytic leukemia: analysis of cytogenetic abnormalities, immunophenotypic profiles, and immunoglobulin heavy chain gene usage. Am J Clin Pathol (2007) 0.84
The longitudinal effects of physical activity and dietary calcium on bone mass accrual across stages of pubertal development. J Bone Miner Res (2015) 0.83
Multiple mechanisms of Erbb2 action after ultraviolet irradiation of the skin. Mol Carcinog (2007) 0.82
12-O-tetradecanoylphorbol-13-acetate and UV radiation-induced nucleoside diphosphate protein kinase B mediates neoplastic transformation of epidermal cells. J Biol Chem (2003) 0.81
Accelerated elimination of ultraviolet-induced DNA damage through apoptosis in CDC25A-deficient skin. Carcinogenesis (2012) 0.81
Harvey-ras gene expression and epidermal cell proliferation in dibenzo[a,l]pyrene-treated early preneoplastic SENCAR mouse skin. J Invest Dermatol (2005) 0.80
The epidermal growth factor receptor increases cytokine production and cutaneous inflammation in response to ultraviolet irradiation. ISRN Dermatol (2013) 0.80
The human promyelocytic leukemia protein is a tumor suppressor for murine skin carcinogenesis. Mol Carcinog (2009) 0.79
Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry. Fam Cancer (2013) 0.78
The selection and prevalence of natural and fortified calcium food sources in the diets of adolescent girls. J Nutr Educ Behav (2011) 0.78
Aspirin use is associated with lower prostate cancer risk in male carriers of BRCA mutations. J Genet Couns (2013) 0.77
Mouse skin models for carcinogenic hazard identification: utilities and challenges. Toxicol Pathol (2007) 0.77
Observations on the development of the acetabulum following Chiari osteotomy. Iowa Orthop J (2002) 0.76
Development of innervation to maxillary whiskers in mice. Anat Rec (Hoboken) (2010) 0.75
Prevalence of extra-esophageal cancers in patients with Barrett's esophagus and esophageal adenocarcinoma. Trop Gastroenterol (2013) 0.75
Mechanisms of SEPA 0009-induced tumorigenesis in v-rasHa transgenic Tg.AC mice. Toxicol Pathol (2005) 0.75